TABLE 4.
Summary of comparative changes in the relative levels of cytokine mRNA expression in faucal biopsies from cats with FCGS after 3 months of treatment grouped by change in fauces clinical score and treatment received
| Groupa | No. of cats/group | Comparative changes in relative levels of
cytokine mRNA expressionb
|
||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IL-2
|
IL-4
|
IL-6
|
IL-10
|
IL-12
p35
|
IL-12 p40
|
IFN-γ
|
||||||||||||||||
| ↑ | ↓ | ND | ↑ | ↓ | ND | ↑ | ↓ | ND | ↑ | ↓ | ND | ↑ | ↓ | ND | ↑ | ↓ | ND | ↑ | ↓ | ND | ||
| Change in fauces clinical score | ||||||||||||||||||||||
| No change | 14 | 4 | 7 | 3 | 2 | 3 | 9 | 3 | 9 | 2 | 5 | 6 | 3 | 4 | 5 | 5 | 7 | 3 | 4 | 7 | 5 | 2 |
| Reduced | 9 | 5 | 3 | 1 | 1 | 0 | 8 | 1 | 7 | 1 | 2 | 6 | 1 | 2 | 5 | 2 | 4 | 4 | 1 | 2 | 6 | 1 |
| P valuec | 0.37 | NA | 0.62 | 0.63 | 0.63 | 0.63 | 0.20 | |||||||||||||||
| Treatment | ||||||||||||||||||||||
| OH | 6 | 3 | 2 | 1 | 1 | 1 | 4 | 1 | 4 | 1 | 1 | 4 | 1 | 2 | 2 | 2 | 3 | 1 | 2 | 3 | 2 | 1 |
| Myo | 4 | 3 | 0 | 1 | 0 | 0 | 4 | 1 | 2 | 1 | 1 | 2 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 |
| MePred | 7 | 3 | 3 | 1 | 0 | 2 | 5 | 1 | 5 | 1 | 3 | 2 | 2 | 0 | 4 | 3 | 3 | 3 | 1 | 2 | 4 | 1 |
| Met/Spir | 6 | 0 | 5 | 1 | 2 | 0 | 4 | 1 | 5 | 0 | 2 | 4 | 0 | 2 | 3 | 1 | 3 | 2 | 1 | 2 | 4 | 0 |
a
OH, oral hygiene; Myo, myocrisin; MePred, methylprednisolone; Met/Spir, metronidazole and spiramycin.
b
↑, Increase in relative cytokine mRNA expression after treatment; ↓, decrease in relative cytokine expression after treatment; ND, change in relative cytokine mRNA was not determinable.
c
Fisher’s exact test (“ND” cases were excluded); NA, not applied.